Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modified non-clarithromycin triple therapy
- Development stage
- Unknown
- Lead developer
- Phathom Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Modified non-clarithromycin triple therapy refers to a combination regimen for the eradication of Helicobacter pylori infection that includes a proton pump inhibitor (PPI) and two antibiotics, but specifically excludes clarithromycin due to rising resistance rates. The most common modifications substitute clarithromycin with other antibiotics such as metronidazole, levofloxacin, or rifabutin. These regimens are used as alternatives in regions or patient populations where clarithromycin resistance is high or when prior treatment with clarithromycin has failed. The mechanism of action involves suppression of gastric acid secretion by the PPI (enhancing antibiotic efficacy) and direct antibacterial effects from the two chosen antibiotics against H. pylori[1][3][5]. This approach is recommended in recent guidelines as an initial or salvage treatment for H. pylori infection.
- Other names
- non-clarithromycin triple therapyPPI-based non-clarithromycin triple therapy
02
Targets
NeuraminidaseATP4A (Potassium–transporting ATPase alpha chain 1)DNA gyrasePBP (Penicillin-binding protein family)RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on modified non-clarithromycin triple therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modified non-clarithromycin triple therapy.